Bank Of New York Mellon Corp Alzamend Neuro, Inc. Transaction History

Bank Of New York Mellon Corp

  • $528 Trillion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023
BUY
$0.37 - $0.71 $14,935 - $28,660
40,367 New
40,367 $17.2 Million
Q4 2022

Feb 14, 2023
BUY
$0.53 - $222.0 $21,394 - $8.96 Million
40,367 New
40,367 $22,000

About Alzamend Neuro, Inc.

ALZN Quotes by TradingView
  • Ticker ALZN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 95,481,800
  • Market Cap $159M
  • Description
  • Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...
More about ALZN
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email